Olney's lesions: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
== Olney's Lesions == | |||
[[File:Fnana-07-00023-g002.jpg|thumb|right|Histological image showing Olney's lesions in the rat brain.]] | |||
[[ | |||
'''Olney's lesions''' are a type of brain damage that was first observed in laboratory animals by Dr. John Olney in the 1980s. These lesions are characterized by vacuoles, or small cavities, that form in the brain tissue, particularly in the [[cerebral cortex]] and [[thalamus]]. They are associated with the use of certain [[NMDA receptor antagonists]], such as [[dizocilpine]] (MK-801) and [[phencyclidine]] (PCP). | |||
== | == Pathophysiology == | ||
Olney's lesions are believed to result from the blockade of [[NMDA receptors]], which are critical for normal synaptic transmission and [[neuroplasticity]]. When these receptors are inhibited, it leads to a cascade of events that result in the formation of vacuoles within neurons. This process is thought to involve the disruption of normal [[calcium]] homeostasis and the activation of [[apoptotic]] pathways. | |||
== | == Clinical Significance == | ||
* [[NMDA receptor | |||
* [[ | While Olney's lesions have been extensively studied in animal models, their relevance to humans remains a topic of debate. Some researchers have raised concerns about the potential for similar lesions to occur in humans who use NMDA receptor antagonists, such as [[ketamine]], for recreational purposes or as part of [[anesthetic]] procedures. However, definitive evidence of Olney's lesions in humans is lacking. | ||
== Research and Controversy == | |||
Research into Olney's lesions has provided valuable insights into the effects of NMDA receptor antagonists on the brain. However, the topic remains controversial, particularly regarding the implications for human health. Some studies suggest that the doses required to produce Olney's lesions in animals are much higher than those typically used in clinical settings, while others caution against the potential risks of chronic exposure. | |||
== Related Pages == | |||
* [[NMDA receptor]] | |||
* [[Neurotoxicity]] | |||
* [[Ketamine]] | |||
* [[Phencyclidine]] | * [[Phencyclidine]] | ||
* [[ | * [[Anesthesia]] | ||
[[Category: | [[Category:Neurotoxicity]] | ||
[[Category: | [[Category:Neurology]] | ||
Latest revision as of 11:58, 15 February 2025
Olney's Lesions[edit]
Olney's lesions are a type of brain damage that was first observed in laboratory animals by Dr. John Olney in the 1980s. These lesions are characterized by vacuoles, or small cavities, that form in the brain tissue, particularly in the cerebral cortex and thalamus. They are associated with the use of certain NMDA receptor antagonists, such as dizocilpine (MK-801) and phencyclidine (PCP).
Pathophysiology[edit]
Olney's lesions are believed to result from the blockade of NMDA receptors, which are critical for normal synaptic transmission and neuroplasticity. When these receptors are inhibited, it leads to a cascade of events that result in the formation of vacuoles within neurons. This process is thought to involve the disruption of normal calcium homeostasis and the activation of apoptotic pathways.
Clinical Significance[edit]
While Olney's lesions have been extensively studied in animal models, their relevance to humans remains a topic of debate. Some researchers have raised concerns about the potential for similar lesions to occur in humans who use NMDA receptor antagonists, such as ketamine, for recreational purposes or as part of anesthetic procedures. However, definitive evidence of Olney's lesions in humans is lacking.
Research and Controversy[edit]
Research into Olney's lesions has provided valuable insights into the effects of NMDA receptor antagonists on the brain. However, the topic remains controversial, particularly regarding the implications for human health. Some studies suggest that the doses required to produce Olney's lesions in animals are much higher than those typically used in clinical settings, while others caution against the potential risks of chronic exposure.
